FibroBiologicsFBLG
FBLG
About: FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.
Employees: 13
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
77% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 13
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
2% more funds holding
Funds holding: 64 [Q4 2024] → 65 (+1) [Q1 2025]
0.55% more ownership
Funds ownership: 17.1% [Q4 2024] → 17.64% (+0.55%) [Q1 2025]
51% less capital invested
Capital invested by funds: $11.9M [Q4 2024] → $5.81M (-$6.04M) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$12
1,384%
upside
Avg. target
$14
1,631%
upside
High target
$16
1,878%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert | 1,878%upside $16 | Buy Maintained | 15 May 2025 |
HC Wainwright & Co. Matthew Caufield | 1,384%upside $12 | Buy Reiterated | 1 Apr 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
6 days ago
FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer
Seasoned finance executive brings over 20 years of public company and capital markets experience to support clinical-stage growth Seasoned finance executive brings over 20 years of public company and capital markets experience to support clinical-stage growth
Neutral
GlobeNewsWire
1 month ago
FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting
HOUSTON, May 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Senior Research Scientist, Dr. Chuo Fang M.D., Ph.D., delivered a poster presentation at the Society for Investigative Dermatology (SID) Annual Meeting that took place in San Diego May 7-10, 2025. The SID Annual Meeting provides a premier forum for skin biology research and education for researchers to share transformative scientific discoveries and medical innovations that improve human health.
Neutral
GlobeNewsWire
1 month ago
FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the third quarter of 2025 Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the third quarter of 2025
Neutral
GlobeNewsWire
1 month ago
FibroBiologics Presenting at the ThymUS 2025 Meeting
HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Simon Gebremeskel, research scientist at FibroBiologics, is presenting a poster at the ThymUS 2025 Meeting taking place in Lihue, Kaua'i Hawaii from April 27 - May 1, 2025. Founded in 2001, ThymUS brings together international researchers working on thymus and T-cell biology.
Neutral
GlobeNewsWire
1 month ago
FibroBiologics Presents at the ThymUS 2025 Meeting
HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Simon Gebremeskel, research scientist at FibroBiologics, is presenting a poster at the ThymUS 2025 Meeting taking place in Lihue, Kaua'i Hawaii from April 27 - May 1, 2025. Founded in 2001, ThymUS brings together international researchers working on thymus and T-cell biology.
Neutral
GlobeNewsWire
2 months ago
FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean
HOUSTON, April 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics, will present on FibroBiologics' unique fibroblast cell-based approach for the potential treatment of chronic diseases at The Cell & Gene Meeting On The Mediterranean (Med) in Rome, Italy, from April 15-17, 2025. The Cell & Gene Meeting on the Med is the leading conference bringing together the Advanced Therapy Medicinal Products community from Europe and beyond.
Neutral
GlobeNewsWire
2 months ago
FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics
Located in Houston, Texas, the new facility allows FibroBiologics to expand its research and development efforts utilizing fibroblast-based technology Located in Houston, Texas, the new facility allows FibroBiologics to expand its research and development efforts utilizing fibroblast-based technology
Neutral
GlobeNewsWire
2 months ago
FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair
HOUSTON, April 02, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced a significant advancement in neurodegenerative disease research. Leveraging the well-established Cuprizone animal model, FibroBiologics has demonstrated that intravenous fibroblasts can facilitate remyelination.
Neutral
GlobeNewsWire
2 months ago
FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update
Proprietary master cell bank of fibroblast-based spheroids product candidate, CYWC628, completed in accordance with Good Manufacturing Practices after successfully passing all required safety testing
Neutral
GlobeNewsWire
2 months ago
FibroBiologics Announces 2025 Annual Meeting of Stockholders
HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that its 2025 Annual Meeting of Stockholders will take place on June 12, 2025, at 11 a.m. CDT, exclusively through a virtual format. The record date for determination of stockholders entitled to vote at the annual meeting is April 14, 2025.
Charts implemented using Lightweight Charts™